218 related articles for article (PubMed ID: 34023505)
1. A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer.
Bertolini G; Cancila V; Milione M; Lo Russo G; Fortunato O; Zaffaroni N; Tortoreto M; Centonze G; Chiodoni C; Facchinetti F; Pollaci G; Taiè G; Giovinazzo F; Moro M; Camisaschi C; De Toma A; D'Alterio C; Pastorino U; Tripodo C; Scala S; Sozzi G; Roz L
Mol Ther; 2021 Oct; 29(10):2963-2978. PubMed ID: 34023505
[TBL] [Abstract][Full Text] [Related]
2. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.
Bertolini G; Roz L; Perego P; Tortoreto M; Fontanella E; Gatti L; Pratesi G; Fabbri A; Andriani F; Tinelli S; Roz E; Caserini R; Lo Vullo S; Camerini T; Mariani L; Delia D; Calabrò E; Pastorino U; Sozzi G
Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16281-6. PubMed ID: 19805294
[TBL] [Abstract][Full Text] [Related]
3. CXCR4 Inhibition Counteracts Immunosuppressive Properties of Metastatic NSCLC Stem Cells.
Fortunato O; Belisario DC; Compagno M; Giovinazzo F; Bracci C; Pastorino U; Horenstein A; Malavasi F; Ferracini R; Scala S; Sozzi G; Roz L; Roato I; Bertolini G
Front Immunol; 2020; 11():02168. PubMed ID: 33123122
[TBL] [Abstract][Full Text] [Related]
4. Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches.
Roy LD; Sahraei M; Schettini JL; Gruber HE; Besmer DM; Mukherjee P
BMC Cancer; 2014 Mar; 14():225. PubMed ID: 24674692
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
Fahham D; Weiss ID; Abraham M; Beider K; Hanna W; Shlomai Z; Eizenberg O; Zamir G; Izhar U; Shapira OM; Peled A; Wald O
J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1167-1175.e1. PubMed ID: 22925564
[TBL] [Abstract][Full Text] [Related]
6. CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche.
Kim M; Koh YJ; Kim KE; Koh BI; Nam DH; Alitalo K; Kim I; Koh GY
Cancer Res; 2010 Dec; 70(24):10411-21. PubMed ID: 21056990
[TBL] [Abstract][Full Text] [Related]
7. Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM- Lung Cancer-Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis.
Bertolini G; D'Amico L; Moro M; Landoni E; Perego P; Miceli R; Gatti L; Andriani F; Wong D; Caserini R; Tortoreto M; Milione M; Ferracini R; Mariani L; Pastorino U; Roato I; Sozzi G; Roz L
Cancer Res; 2015 Sep; 75(17):3636-49. PubMed ID: 26141860
[TBL] [Abstract][Full Text] [Related]
8. IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis.
Panneerselvam J; Jin J; Shanker M; Lauderdale J; Bates J; Wang Q; Zhao YD; Archibald SJ; Hubin TJ; Ramesh R
PLoS One; 2015; 10(3):e0122439. PubMed ID: 25775124
[TBL] [Abstract][Full Text] [Related]
9. Combination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of CD133+ Tumor-Initiating Cells and Reveals Heterogeneity of Cancer Stem Cell Compartment in Lung Cancer.
Moro M; Bertolini G; Pastorino U; Roz L; Sozzi G
J Thorac Oncol; 2015 Jul; 10(7):1027-36. PubMed ID: 26020124
[TBL] [Abstract][Full Text] [Related]
10. Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma.
Hao C; Liu G; Tian G
Ther Adv Respir Dis; 2019; 13():1753466619866097. PubMed ID: 31368411
[TBL] [Abstract][Full Text] [Related]
11. CXCR4 is involved in CD133-induced EMT in non-small cell lung cancer.
Tu Z; Xie S; Xiong M; Liu Y; Yang X; Tembo KM; Huang J; Hu W; Huang X; Pan S; Liu P; Altaf E; Kang G; Xiong J; Zhang Q
Int J Oncol; 2017 Feb; 50(2):505-514. PubMed ID: 28000861
[TBL] [Abstract][Full Text] [Related]
12. The CXCR4/SDF-1 chemokine receptor axis: a new target therapeutic for non-small cell lung cancer.
Otsuka S; Bebb G
J Thorac Oncol; 2008 Dec; 3(12):1379-83. PubMed ID: 19057260
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin targets the stromal cell-derived factor-1-CXC chemokine receptor type 4 axis to suppress metastasis and invasion of ovarian cancer-initiating cells.
Yu ZH; Liu T; Zhao YH; Huang YY; Gao YT
Tumour Biol; 2014 May; 35(5):4637-44. PubMed ID: 24408020
[TBL] [Abstract][Full Text] [Related]
14. CXCR4 antagonists suppress small cell lung cancer progression.
Taromi S; Kayser G; Catusse J; von Elverfeldt D; Reichardt W; Braun F; Weber WA; Zeiser R; Burger M
Oncotarget; 2016 Dec; 7(51):85185-85195. PubMed ID: 27835905
[TBL] [Abstract][Full Text] [Related]
15. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.
Peng SB; Zhang X; Paul D; Kays LM; Gough W; Stewart J; Uhlik MT; Chen Q; Hui YH; Zamek-Gliszczynski MJ; Wijsman JA; Credille KM; Yan LZ
Mol Cancer Ther; 2015 Feb; 14(2):480-90. PubMed ID: 25504752
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells.
Jung MJ; Rho JK; Kim YM; Jung JE; Jin YB; Ko YG; Lee JS; Lee SJ; Lee JC; Park MJ
Oncogene; 2013 Jan; 32(2):209-21. PubMed ID: 22370645
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-inducible factor 1α (HIF-1α) and reactive oxygen species (ROS) mediates radiation-induced invasiveness through the SDF-1α/CXCR4 pathway in non-small cell lung carcinoma cells.
Gu Q; He Y; Ji J; Yao Y; Shen W; Luo J; Zhu W; Cao H; Geng Y; Xu J; Zhang S; Cao J; Ding WQ
Oncotarget; 2015 May; 6(13):10893-907. PubMed ID: 25843954
[TBL] [Abstract][Full Text] [Related]
18. LRP6 Ectodomain Prevents SDF-1/CXCR4-Induced Breast Cancer Metastasis to Lung.
Zhang J; Chen J; Wo D; Yan H; Liu P; Ma E; Li L; Zheng L; Chen D; Yu Z; Liang C; Peng J; Ren DN; Zhu W
Clin Cancer Res; 2019 Aug; 25(15):4832-4845. PubMed ID: 31010839
[TBL] [Abstract][Full Text] [Related]
19. Adenosine A2A receptor activation reduces brain metastasis via SDF-1/CXCR4 axis and protecting blood-brain barrier.
Chen L; Li L; Zhou C; Chen X; Cao Y
Mol Carcinog; 2020 Apr; 59(4):390-398. PubMed ID: 32037613
[TBL] [Abstract][Full Text] [Related]
20. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression.
Perissinotto E; Cavalloni G; Leone F; Fonsato V; Mitola S; Grignani G; Surrenti N; Sangiolo D; Bussolino F; Piacibello W; Aglietta M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):490-7. PubMed ID: 15701832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
